Author

Christopher Ma

Expanding Horizons in EoE: The Journey to Long-Term Disease Control (Sanofi Regeneron) (Complete Session)
Expanding Horizons in EoE: The Journey to Long-Term Disease Control (Sanofi Regeneron) (Complete Session)

Christopher Ma  et al.

MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS USTEKINUMAB ON ENDOSCOPIC OUTCOMES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS USTEKINUMAB ON ENDOSCOPIC OUTCOMES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Christopher Ma  et al.

BURDEN OF ILLNESS AND TREATMENT PATTERNS OF EOSINOPHILIC OESOPHAGITIS PATIENTS: EVIDENCE FROM A MULTINATIONAL MEDICAL RECORD REVIEW
BURDEN OF ILLNESS AND TREATMENT PATTERNS OF EOSINOPHILIC OESOPHAGITIS PATIENTS: EVIDENCE FROM A MULTINATIONAL MEDICAL RECORD REVIEW

Christopher Ma  et al.

AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS
AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS

Christopher Ma  et al.

COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB, VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AFTER ONE-YEAR MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 3 MATCHING-ADJUSTED INDIRECT COMPARISONS
COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB, VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AFTER ONE-YEAR MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 3 MATCHING-ADJUSTED INDIRECT COMPARISONS

Christopher Ma  et al.

ASSESSMENT OF THE FATTY ACID PROFILE OF THE ERYTHROCYTE MEMBRANE IN PATIENTS FOLLOWING THE CROHN’S DISEASE THERAPEUTIC DIETARY INTERVENTION (CD-TDI): A PRELIMINARY STUDY
ASSESSMENT OF THE FATTY ACID PROFILE OF THE ERYTHROCYTE MEMBRANE IN PATIENTS FOLLOWING THE CROHN’S DISEASE THERAPEUTIC DIETARY INTERVENTION (CD-TDI): A PRELIMINARY STUDY

Christopher Ma  et al.

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1

Christopher Ma  et al.

​ENDOSCOPIC SCORING INDICES FOR ASSESSING DISEASE SEVERITY IN FAMILIAL ADENOMATOUS POLYPOSIS: A SYSTEMATIC REVIEW
​ENDOSCOPIC SCORING INDICES FOR ASSESSING DISEASE SEVERITY IN FAMILIAL ADENOMATOUS POLYPOSIS: A SYSTEMATIC REVIEW

Christopher Ma  et al.

THE CROHN’S DISEASE THERAPEUTIC DIET INTERVENTION (CD-TDI) FOR REDUCING INFLAMMATION IN MILD-MODERATELY ACTIVE CROHN’S DISEASE: A PRELIMINARY ANALYSIS
THE CROHN’S DISEASE THERAPEUTIC DIET INTERVENTION (CD-TDI) FOR REDUCING INFLAMMATION IN MILD-MODERATELY ACTIVE CROHN’S DISEASE: A PRELIMINARY ANALYSIS

Christopher Ma  et al.

PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Christopher Ma  et al.

INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
INTERLEUKIN-23 AND INTERLEUKIN-12/23 INHIBITORS FOR THE TREATMENT OF CROHN’S DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS

Christopher Ma  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Christopher Ma  et al.

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2
A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

Christopher Ma  et al.

Item 1 - 13 / 13
1